LeadIQ logo
Learn more at LeadIQ.com

Insights

Expansion into US Market Immunovia is actively preparing to launch its pancreatic cancer diagnostic test PancreaSure in the United States in the second half of 2025. This presents a significant opportunity for sales teams to engage with hospital networks, biotech firms, and healthcare providers interested in innovative early detection tools.

Strategic Facility Relocation The company has recently moved its U.S. laboratory and headquarters to North Carolina's Research Triangle Park, a major biotech hub. This shift facilitates closer collaboration with local research institutions and biotech firms, opening doors for partnership and sales opportunities in diagnostics and medical research services.

Focused Oncology Innovation Immunovia specializes in highly accurate blood tests for early pancreatic cancer detection, which aligns with the growing trend toward precision medicine and early intervention. Sales efforts can target oncology clinics, diagnostic labs, and healthcare providers seeking advanced tumor detection technologies.

Investment & Growth Outlook With a revenue range of $10M to $25M and recent funding of $4.5M, Immunovia appears poised for growth and product expansion. This funding indicates an openness to strategic partnerships and sales of their diagnostic solutions to expand their market reach.

Key Leadership Changes Recent leadership updates, including the appointment of Dr. Lisa Ford as Clinical Laboratory Director and Norma Alonzo Palma as Vice President of Clinical and Medical Affairs, signal a focus on strengthening clinical validation and commercial scaling—ideal touchpoints for aligning sales strategies with their growth trajectory.

Similar companies to Immunovia AB

Immunovia AB Tech Stack

Immunovia AB uses 8 technology products and services including Microsoft 365, Font Awesome, jQuery, and more. Explore Immunovia AB's tech stack below.

  • Microsoft 365
    Email
  • Font Awesome
    Font Scripts
  • jQuery
    Javascript Libraries
  • jQuery Migrate
    Javascript Libraries
  • Microsoft
    Miscellaneous
  • DX Delivery Service
    Transportation And Fleet Management
  • Contact Form 7
    Web Platform Extensions
  • Apache HTTP Server
    Web Servers

Media & News

Immunovia AB's Email Address Formats

Immunovia AB uses at least 1 format(s):
Immunovia AB Email FormatsExamplePercentage
First.Last@immunovia.comJohn.Doe@immunovia.com
49%
First.MiddleLast@immunovia.comJohn.MichaelDoe@immunovia.com
1%
FLast@immunovia.comJDoe@immunovia.com
1%
First.Last@immunovia.comJohn.Doe@immunovia.com
49%

Frequently Asked Questions

Where is Immunovia AB's headquarters located?

Minus sign iconPlus sign iconImmunovia AB's main headquarters is located at Medicon Village, Scheelevägen 2 Lund, 22381, SE. The company has employees across 2 continents, including North AmericaEurope.

What is Immunovia AB's phone number?

Minus sign iconPlus sign icon You can contact Immunovia AB's main corporate office by phone at
+46-46-275-6****
. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Immunovia AB's official website and social media links?

Minus sign iconPlus sign iconImmunovia AB's official website is immunovia.com and has social profiles on LinkedInCrunchbase.

What is Immunovia AB's SIC code NAICS code?

Minus sign iconPlus sign iconImmunovia AB's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Immunovia AB have currently?

Minus sign iconPlus sign iconAs of October 2025, Immunovia AB has approximately 51 employees across 2 continents, including North AmericaEurope. Key team members include Vice President Clinical And Medical Affairs: N. A. P.Vice President, Market Access & Reimbursement: N. C.Non Executive Director: M. M.. Explore Immunovia AB's employee directory with LeadIQ.

What industry does Immunovia AB belong to?

Minus sign iconPlus sign iconImmunovia AB operates in the Biotechnology Research industry.

What technology does Immunovia AB use?

Minus sign iconPlus sign iconImmunovia AB's tech stack includes Microsoft 365Font AwesomejQueryjQuery MigrateMicrosoftDX Delivery ServiceContact Form 7Apache HTTP Server.

What is Immunovia AB's email format?

Minus sign iconPlus sign iconImmunovia AB's email format typically follows the pattern of First.Last@immunovia.com. Find more Immunovia AB email formats with LeadIQ.

How much funding has Immunovia AB raised to date?

Minus sign iconPlus sign icon As of October 2025, Immunovia AB has raised $4.5M in funding. The last funding round occurred on Aug 05, 2024 for $4.5M.

When was Immunovia AB founded?

Minus sign iconPlus sign iconImmunovia AB was founded in 2007.

Immunovia AB

Biotechnology ResearchSweden51-200 Employees

Immunovia AB (publ.) is a lean, focused diagnostic company seeking to revolutionize early detection of pancreatic cancer. We aim to improve outcomes for people at high risk of pancreatic cancer by detecting the disease at Stage 1 or 2 with our highly accurate blood test, PancreaSure. Immunovia plans to launch PancreaSure in the United States in the second half of 2025.

Immunovia was founded in Lund, Sweden based on protein research at Lund University. The company’s clinical lab and many of its employees are in the U.S.A., the company’s first commercial market.

Immunovia stock trades on the Nasdaq Stockholm exchange under the ticker symbol IMMNOV. Visit our website for more information.

Section iconCompany Overview

Headquarters
Medicon Village, Scheelevägen 2 Lund, 22381, SE
Phone number
+46-46-275-6****
Website
immunovia.com
SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2007
Employees
51-200

Section iconMedia & News

Section iconFunding & Financials

  • $4.5M

    Immunovia AB has raised a total of $4.5M of funding over 5 rounds. Their latest funding round was raised on Aug 05, 2024 in the amount of $4.5M.

  • $10M$25M

    Immunovia AB's revenue is estimated to be in the range of $10M$25M

Section iconFunding & Financials

  • $4.5M

    Immunovia AB has raised a total of $4.5M of funding over 5 rounds. Their latest funding round was raised on Aug 05, 2024 in the amount of $4.5M.

  • $10M$25M

    Immunovia AB's revenue is estimated to be in the range of $10M$25M

Company Leadership

  • Stylized image of a person
    N. A. P.
    Vice President Clinical And Medical Affairs
    Phone icon
    Mobile Phone
  • Stylized image of a person
    N. C.
    Vice President, Market Access & Reimbursement
    Phone icon
    Mobile Phone
  • Stylized image of a person
    M. M.
    Non Executive Director
    Phone icon
    Mobile Phone
  • Stylized image of a person
    L. F.
    Clinical Laboratory Director
    Phone icon
    Mobile Phone
  • Stylized image of a person
    T. K.
    Medical Director
    Phone icon
    Mobile Phone

Employee Directory

  • Stylized image of a person
    K. H.
    Associate Director Of Biostatistics And Clinical Data Management
    Phone icon
    Mobile Phone
  • Stylized image of a person
    J. M.
    Laboratory Director
    Phone icon
    Mobile Phone
  • Stylized image of a person
    M. H. C.
    Laboratory Director
    Phone icon
    Mobile Phone
  • Stylized image of a person
    M. H. C.
    Laboratory Director
    Phone icon
    Mobile Phone
  • Stylized image of a person
    L. D.
    Clinical Trial Manager
    Phone icon
    Mobile Phone

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust LeadIQ to help them build pipeline confidently.

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.